This article highlights the bipartisan nature of the user fee reauthorization legislation and quotes Catalyst President Nancy Myers on the similarities between the House and Senate versions: “I would say it’s pretty surprising how significantly they lined up,” she says in the article. “The politicians realized that each one of these user fee agreements had good agreement between the agency and industry. They realized that with an election year, if they wanted to go home and claim to have done something significant on the healthcare front that actually helps people get the medicines they need, that a bipartisan agreement needed to be done carefully and quickly.”
FDA Reform Legislation Emerges as Exception to Washington Gridlock
Genetic Engineering & Biotechnology News